Table 2.
Overview of mutations in selected genes in classic Hodgkin, large cell, and aggressive B‐cell lymphomas
| Pathway | Gene | BL (%) | DLBCL (%) | PMBCL (%) | cHL (%) | PBL (%) |
|---|---|---|---|---|---|---|
| JAK‐STAT | SOCS1 | ST2 | 40–50 | 30–40 | 5–10 | |
| STAT3 | ST2 | 5–15 | 30–40 | |||
| STAT6 | <5 | 30–40 | 30–40 | |||
| JAK1 | 5–15 | 10–20% | ||||
| MAPK | NRAS | 10–20% | ||||
| KRAS | <5 | 5–10 | ||||
| BcR | CD79B | MCD | ||||
| CARD11 | 5–15 | |||||
| Epigenetic | KMT2D | 5–10 | EZB | 5–15 | ||
| CREBBP | 5–10 | EZB | 5–10 | |||
| EP300 | EZB | 10–20% | ||||
| EZH2 | EZB | 10–20% | 30–40 | |||
| HIST1 a | 30–40 | 5–15 | 20–30 | 10–20% | ||
| ARID1A | 5–10 | 10–20 | ||||
| TET2 | ST2 | <5 | 5–15 | |||
| ZNF217 | 20–30 | 10–20% | ||||
| Cell cycle | MYC | 40–50 | 5–15 | 10–20% | ||
| DNA damage | TP53 | 10–20% | 10–20% | 10–20% | 5–10 | 20–30 |
| ATM | <5 | <5 | 5–15 | |||
| NF‐κB | NFKBIE | <5 | 10–20% | 10–20% | ||
| NOTCH | NOTCH1 | 5–10 | N1 | <5 | ||
| NOTCH2 | BN2 | <5 | ||||
| SPEN | 5–10 | 5–15 | ||||
| TLR | MYD88 | MCD | ||||
| Apoptosis | BCL2 | EZBb | ||||
| Immune | TNFRSF14 | EZB | <5 | |||
| CXCR4 | <5 | <5 | ||||
| B2M | 5–10 | 20–30 | 20–30 | |||
| TNFAIP3 | BN2 | 20–30 | 20–30 | |||
| IL4R | 20–30 | |||||
| Transcription | ID3 | 30–40 | <5 | |||
| TCF3 | 20–30 | |||||
| KLF2 | 5–15 | <5 | ||||
| Others | PTPN1 | 20–30 | 20–30 |
| Mutation frequency ranges (%) | ||||||
|---|---|---|---|---|---|---|
| <5 | 20–30 | |||||
| 5–10 | 30–40 | |||||
| 5–15 | 40–50 | |||||
| 10–20 | >90 | |||||
Note: Frequency ranges are approximated, in a majority of cases stemming from two or more studies. In the DLBCL column, EZB, BN2, MCD, N1, and ST2 denote mutations typically present in the said molecular subtype.
Abbreviations: BcR, B‐cell receptor; BL, Burkitt lymphoma; BN2, BCL6 fusion and NOTCH2 mutation; cHL, classic Hodgkin lymphoma; DLBCL, diffuse large B‐cell lymphoma; EZB, EZH2 mutation and BCL2 translocation; MCD, MYD88 and CD79B mutations; N1, NOTCH1 mutation; PBL, plasmablastic lymphoma; PMBCL, primary mediastinal B‐cell lymphoma; ST2, SGK1 and TET2 mutations; TLR, toll‐like receptor.
a
HIST1 gene family.
b
BCL2 translocation.